Cagrilintide Research: Trials, Data & What the Studies Show
Cagrilintide is a long-acting amylin analog that works through receptors GLP-1 drugs do not touch. Here is what the published monotherapy and CagriSema combination data actually report.
Mechanism of action
Amylin is a hormone co-secreted with insulin by the pancreas after a meal; it signals satiety to the brainstem. Natural amylin is short-lived and aggregation-prone, which is why it was never usable as a weekly therapeutic.
Cagrilintide is a synthetic amylin analog modified with a fatty acid chain (lipidation). That chain binds albumin in circulation, extending half-life enough to support once-weekly subcutaneous administration while preventing the aggregation that limits native amylin.
Pharmacologically it behaves as a dual amylin and calcitonin receptor agonist (DACRA), acting on receptor populations separate from those used by GLP-1 agonists — which is the mechanistic basis for combining it with Semaglutide rather than substituting for it.
The studies
Cagrilintide has an unusually mature clinical record for a research peptide: Novo Nordisk has run it through phase 2 and phase 3 both as monotherapy and as the CagriSema fixed combination with Semaglutide. It is still in regulatory review and is not an approved medicine.
Mechanism
Amylin and calcitonin receptor signalling in the hindbrain
Whether activating amylin receptors reduces appetite through neural circuits that are independent of GLP-1 receptor signalling.
Structural and mechanistic receptor-binding work mapping DACRA activity in hindbrain and brainstem nuclei
- Amylin + calcitonin (DACRA)
- Receptor profile
- Engaged
- Homeostatic centres
- Engaged
- Hedonic / reward centres
- Cagrilintide acts as a dual amylin and calcitonin receptor agonist rather than through the GLP-1 receptor.
- It engages both homeostatic (hunger) and hedonic (craving/reward) circuitry in the brainstem.
- Because the receptor targets differ from GLP-1 agonists, the two do not compete — this is the rationale for combination dosing.
Monotherapy
Cagrilintide 2.4 mg as standalone therapy (REDEFINE 1 programme)
Whether a long-acting amylin analog produces clinically meaningful weight loss on its own, without a GLP-1 partner.
Double-blind randomised comparison of once-weekly Cagrilintide 2.4 mg against placebo in adults with obesity, with earlier phase 2 dose-ranging as the baseline reference
- ~10.8% to 11.8%
- Mean weight reduction (phase 2 baseline)
- Once weekly, subcutaneous
- Dosing
- Lower than GLP-1 comparators
- Vomiting events
- Standalone Cagrilintide produces weight loss broadly comparable to early-generation GLP-1 therapies.
- Gastrointestinal tolerability — particularly vomiting — was reported as more favourable than GLP-1 comparators.
- Monotherapy is the weaker of the two use cases in the data; the combination results are substantially larger.
Combination therapy
CagriSema: Cagrilintide plus Semaglutide in one weekly injection
What happens when an amylin analog and a GLP-1 agonist are combined into a single weekly formulation.
Randomised controlled trial published in the New England Journal of Medicine · 1,206 participants on combination therapy versus placebo
- 13.7% to 14%
- Early-timeline weight reduction
- Up to ~20%
- Total weight loss at week 68
- ~60%
- Participants reaching ≥20% loss
- ~25%
- Participants reaching ≥30% loss
- The combination outperformed essentially every single-agent anti-obesity compound reported to date.
- Around 60% of participants reached at least 20% total body weight reduction, and roughly a quarter exceeded 30%.
- The magnitude is the strongest argument that amylin and GLP-1 pathways are genuinely additive rather than overlapping.
Cardiometabolic
Glycaemic, lipid and blood pressure outcomes (meta-analysis)
Whether the weight loss translates into measurable improvements in glucose regulation and cardiovascular risk markers.
Pooled analysis of randomised clinical trials tracking glycaemic, lipid, anthropometric and blood pressure endpoints
- 88%
- Prediabetes reverting to normoglycaemia
- Reduced
- HbA1c
- Reduced
- Waist circumference
- Reduced
- Systolic blood pressure
- The metabolic effect extends well beyond scale weight: glycaemic, lipid and blood pressure markers all moved favourably.
- Post-meal glucagon suppression reduces hepatic glucose output, flattening post-prandial excursions.
- 88% of participants with prediabetes returned to normoglycaemia in the pooled data.
Gastrointestinal physiology
Gastric emptying rate versus earlier amylin agents
Whether prolonged satiety is driven in part by slower physical transit of food out of the stomach.
Comparative profiling of digestion speed against historical amylin analogs such as Pramlintide
- Significantly slowed
- Gastric emptying
- Flattened
- Post-meal glucose spikes
- Extended
- Duration of satiety
- Slowed gastric emptying is a measurable, mechanistically distinct contributor to the satiety effect.
- Extended gastric residence time flattens post-prandial glucose excursions independently of insulin action.
- It is also the likely source of the gastrointestinal side effects reported across the trial programme.
Storage & handling
Cagrilintide is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved and never shake — amylin analogs are aggregation-prone under agitation.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.